4D Molecular Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
4D Molecular Therapeutics, Inc. (FDMT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-18
- 4D Molecular Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- 4D Molecular Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- 4D Molecular Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-03-31 was $478.00K.
- 4D Molecular Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $11.59M.
- 4D Molecular Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- 4D Molecular Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $478.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-18 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $11.59M 10-K · filed 2026-03-18 | |
| 2024-09-30 | $11.59M 10-Q · filed 2025-11-10 | ||
| 2022-12-31 | $0.00 10-K · filed 2023-03-15 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | ||
| 2021-12-31 | $478.00K 10-K · filed 2023-03-15 | ||
| 2021-03-31 | $478.00K 10-Q · filed 2022-05-12 | ||
| 2020-12-31 | $0.00 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |